Anavex Life Sciences Corp. (AVXL) dropped 35.15% to $3.69, down $2.00, after regulatory updates revealed that the Committee for Medicinal Products for Human Use - CHMP issued a negative trend vote on its Marketing Authorisation Application for oral blarcamesine in early Alzheimer's disease. A formal decision is expected in December.
The company said it will request a re-examination of the CHMP opinion and intends to submit additional biomarker data. Meanwhile, the U.S. Food and Drug Administration's CDER advised the company to seek a meeting to discuss its Alzheimer's trial results.
On the day of the announcement, AVXL experienced unusually heavy trading volume as investors reacted to the regulatory setback. The stock's 52-week range is $2.65 - $4.50.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.